Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Open-label, non-randomized, parallel assignment, phase 2 trial assessing the safety and
efficacy of distinct temozolomide treatment regimens for patients with AML and poor prognosis